ZBIO · Zenas BioPharma, Inc.
$31.51
+1.33% last session
End-of-day data · close of 2026-09-11
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-6.7
Dividend yield
—
Beta
—
Avg volume
1M
Employees
0K
Daily Change %
1.33%
5 Days Change
-1.79%
10 Days Change
-0.09%
30 Days Change
-0.46%
60 Days Change
12.35%
Month to Day Change
0.97%
Year to Day Change
-11.07%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ZBIO
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-14
Latest call per bank · past 12 months
Morgan Stanley
Equal-Weight$32.00
+2.9% vs priceCitigroup
Buy$41.00
+31.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-14 | Morgan Stanley | Maintains | Equal-Weight | $22.00 → $32.00 |
| 2026-08-14 | Guggenheim | Reiterates | Buy | $55.00 |
| 2026-08-14 | Wedbush | Reiterates | Outperform | $45.00 |
| 2026-05-15 | HC Wainwright & Co. | Reiterates | Buy | $44.00 |
| 2026-05-14 | Morgan Stanley | Maintains | Equal-Weight | $21.00 → $22.00 |
| 2026-03-17 | Citigroup | Maintains | Buy | $43.00 → $41.00 |
| 2026-03-17 | Guggenheim | Maintains | Buy | $45.00 → $55.00 |
| 2026-03-17 | Morgan Stanley | Maintains | Equal-Weight | $19.00 → $21.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 49 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 1.5% above the 50-day MA ($31.05).
- Price vs 200-day MA: Trading 21.6% above the 200-day MA ($25.91).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.24) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($15.20) and high ($43.17).
ZBIO Price Chart
Loading chart for ZBIO…
Fundamentals
About Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.